Literature DB >> 2353648

Effects of isoproterenol on accessory pathway conduction in intermittent or concealed Wolff-Parkinson-White syndrome.

T Yamamoto1, S J Yeh, F C Lin, D L Wu.   

Abstract

The effects of isoproterenol on accessory pathway conduction were evaluated in 24 patients with intermittent and 60 patients with concealed pre-excitation, using atrial and ventricular incremental and extrastimulus testing techniques. The atrial paced cycle length that induced block in the accessory pathway could be compared in 11 of the 24 patients with intermittent preexcitation before and after isoproterenol; it decreased from 622 +/- 212 ms to 408 +/- 128 ms (mean +/- standard deviation) after isoproterenol (p less than 0.01). The anterograde effective refractory period of the accessory pathway could be compared in 5 patients before and after isoproterenol; it decreased from 460 +/- 131 to 310 +/- 48 ms after isoproterenol (p less than 0.01). None of the 60 patients with concealed preexcitation showed ventricular preexcitation with isoproterenol infusion. Eighty-one of the 84 patients had clinically documented supraventricular tachycardia, suggesting the accessory pathway was capable of retrograde conduction. Retrograde study was performed in all 84 patients; 83 had retrograde conduction and the other had no retrograde conduction before and after isoproterenol. The ventricular paced cycle length that induced block in the accessory pathway could be compared in 38 patients before and after isoproterenol; it decreased from 342 +/- 71 to 296 +/- 39 ms after isoproterenol (p less than 0.001). The retrograde effective refractory period of the accessory pathway could be compared in 56 patients; it decreased from 293 +/- 76 to 238 +/- 36 ms after isoproterenol (p less than 0.001). In conclusion, isoproterenol facilitates anterograde and retrograde accessory pathway conduction, but the facilitation of anterograde conduction occurs only in those capable of spontaneous conduction.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2353648     DOI: 10.1016/0002-9149(90)91351-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Intermittent preexcitation indicates "a low-risk" accessory pathway: Time for a paradigm shift?

Authors:  Marek Jastrzębski; Piotr Kukla; Maciej Pitak; Andrzej Rudziński; Adrian Baranchuk; Danuta Czarnecka
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05-12       Impact factor: 1.468

2.  Conduction time oscillations precede the spontaneous termination of human atrioventricular reciprocating tachycardia.

Authors:  D V Exner; L B Mitchell; D G Wyse; R S Sheldon; A M Gillis; P Cassidy; H J Duff
Journal:  J Interv Card Electrophysiol       Date:  2000-04       Impact factor: 1.900

3.  Ultrasound-assisted cannulation of the right internal jugular vein during electrophysiologic studies in children.

Authors:  L Liberman; A J Hordof; D T Hsu; R H Pass
Journal:  J Interv Card Electrophysiol       Date:  2001-06       Impact factor: 1.900

4.  Transient appearance of antegrade conduction via an AV accessory pathway caused by atrial fibrillation in a patient with intermittent Wolff-Parkinson-White syndrome.

Authors:  S Niwano; Y Kitano; M Moriguchi; T Izumi
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

5.  Probable association of tachyarrhythmia with nebulized albuterol in a child with previously subclinical wolff Parkinson white syndrome.

Authors:  Michiel Kroesen; Machiel Maseland; Jaime Smal; Annet Reimer; Petra van Setten
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

6.  Electrophysiological evaluation of Wolff-Parkinson-White syndrome.

Authors:  Beatrice Brembilla-Perrot
Journal:  Indian Pacing Electrophysiol J       Date:  2002-10-01

7.  Orthodromic atrioventricular reentrant tachycardia using a concealed isoproterenol-sensitive accessory pathway.

Authors:  Christian Steinberg; François Philippon; Gilles O'Hara; Jean Champagne
Journal:  Indian Pacing Electrophysiol J       Date:  2019-12-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.